HCPLive Five - Dermatology Updates at AAAAI/WAO 2025

With thousands of attendees from around the world, the AAAAI/WAO Joint Congress 2024 in San Diego, California, reaffirmed its role as a premier event in allergy, asthma, immunology, and dermatology. The conference featured hundreds of new abstracts and late-breaking studies, offering critical insights into emerging treatments, disease mechanisms, and patient care strategies.

As part of our on-site coverage, the HCPLive Allergy team reported live from San Diego, conducting expert interviews and capturing key sessions. In this edition of the HCPLive Five, we highlight our video interviews, including discussions on novel biologics for severe asthma, advancements in food allergy immunotherapy, and high-impact clinical trials presented at the meeting.

Updated Treatment Strategies for Pediatric Atopic Dermatitis in 2025, with Ama Alexis, MD
In this video, Ama Alexis, MD, Clinical Assistant Professor of Pediatrics at NYU Langone and Weill Cornell, discusses the latest updates in pediatric atopic dermatitis and why it's important to be aware of new therapies, understand who may benefit from these therapies, and engage in shared decision making with patients and their families.

Investigating Markers of Early-Onset Atopic Dermatitis, with Amy Eapen, MD

In this video, Amy Eapen, MD, an allergist-immunologist at Henry Ford Health System, discussed her research that found that distinct cord-blood DNA methylation (DNAm) patterns are associated with a risk of early-onset atopic dermatitis by 2 years old. Investigators identified 16 differentially methylated regions linked to early-onset atopic dermatitis.

Confirming Tapinarof’s Efficacy and Safety Across Atopic Dermatitis Severities, with Justin Greiwe, MD
In this video, Justin Greiwe, MD, Bernstein Allergy Group, and Clinical Assistant Professor of Medicine, Division of Immunology, Allergy, and Rheumatology, University of Cincinnati, discussed findings from the phase 3 ADORING 1 and 2 trials that demonstrated that tapinarof was well-tolerated and demonstrated consistent efficacy across body regions in people as young as 2 years old with atopic dermatitis.

Achieving Chronic Spontaneous and Inducible Urticaria Control With Barzolvolimab, with Martin Metz, MD
In this video, Martin Metz, MD, a professor at Charité – Universitätsmedizin in Berlin, discussed findings from 2 phase 2 trials that found that barzolvolimab yielded high rates of disease control in patients with CSU and inducible urticaria. He stressed that how it could benefit the treatment landscapes for both CSU and inducible urticaria, especially since there are no therapies currently approved for the latter indication.

Phase 3 Data Supports Dupilumab’s Approval for CSU, with Thomas Casale, MD
In this video, Thomas Casale, MD, professor of internal medicine at Morsani College of Medicine, University of South Florida, discussed data from the phase 3 LIBERTY-CSU CUPID Study A and Study C that demonstrated that dupilumab (Dupixent) reduced itch and urticaria activity in patients with CSU who were uncontrolled with H1-antihistamines, regardless of body mass index.